Glycated Serum Protein, Lipoprotein (a) and Cystatin C are
now available for use on the VITROS® 5600 Integrated System and
VITROS® 4600 Chemistry System.
RARITAN, New Jersey,
July 16, 2018 /PRNewswire/
-- Ortho Clinical Diagnostics (Ortho), a global leader of in
vitro diagnostics, in collaboration with Diazyme Laboratories, Inc.
is offering three new Microtip Partnership Assays to their
customers. The Microtip Partnership Assay (MPA) program enables
Ortho to validate and offer high value, esoteric testing, in step
with the evolving needs of today's labs. Glycated Serum Protein
(GSP), Lipoprotein (a) (Lp (a)), and Cystatin C assays allow Ortho
to deepen offerings in key disease states: diabetes, cardiac and
renal.
"Our MicroTip Partnership Assay program helps us expand our
reach in delivering innovative, important new assays to our
customers," said Robert Yates,
Ortho's chief operating officer. "Ortho is a leader in testing in
diabetes, cardiac and renal areas, and the three new assays we
announce today further that position and commitment."
The GSP assay enriches and expands Ortho's diabetes menu
offering, adding to recent launches of Insulin, C-Peptide and
Beta-Hydroxybutyrate (MPA). Glycemic monitoring is critical in the
prevention or delay of diabetes related complications and
co-morbidities. Lp (a) expands on Ortho's offering of diagnostic
cardiac markers as an important test for patients who may have a
genetic risk factor for premature cardiovascular disease, including
risk-stratification for myocardial infarction and stroke. Cystatin
C is a key marker for early diagnosis of chronic kidney disease and
complements serum creatinine testing. Combining Cystatin C with
serum creatinine can improve the predictive accuracy for all-cause
mortality and end-stage renal disease as it is a more sensitive
marker in the "creatinine blind range" in kidney testing.
The assays will initially be launched in the United States, Europe, Africa and the Middle East.
About Ortho Clinical Diagnostics
Ortho Clinical
Diagnostics is a global leader of in vitro diagnostics serving the
clinical laboratory and immunohematology communities. Across
hospitals, hospital networks, blood banks and labs in more than 125
countries and territories, Ortho's high-quality products and
services enable health care professionals to make better-informed
treatment decisions. For the immunohematology community, Ortho's
blood typing products help ensure every patient receives blood that
is safe, the right type and the right unit. Ortho brings
sophisticated testing technologies, automation, information
management and interpretation tools to clinical laboratories around
the world to help them run more efficiently and effectively and
improve patient care. Ortho's purpose is to improve and save lives
with diagnostics, and it does that by reimagining what's possible.
This is what has defined Ortho for more than 75 years, and it's
what drives Ortho forward. For more information, visit
www.orthoclinicaldiagnostics.com.
© Ortho Clinical Diagnostics 2018
Logo -
https://mma.prnewswire.com/media/699913/Ortho_Clinical_Diagnostics_Logo.jpg